Huisman MC, Niemeijer ALN, Windhorst AD, et al. - In patients with non–small cell lung cancer, researchers evaluated the uptake of ¹⁸F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer. Researchers conducted plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling. They utilized data from a study with ¹⁸F-BMS-986192 in patients with advanced-stage non–small cell lung cancer eligible for nivolumab treatment if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. They examined 22 tumors in 9 patients. The present study demonstrates that a single-tissue reversible model can be applied to evaluate tumor uptake of the PD-L1 PET tracer ¹⁸F-BMS-986192. The data suggested that SUV at 60 minutes following injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. Further validation of SUV against V_T based on an image-derived input function is recommended to evaluate its predictive value for response assessment during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition.